||1UG3CA257393-01 Interpret this number
||High-Spatial-Resolution Ecm-Inclusive Multi-Omics Sequencing of Human Pfa and Ffpe Tissue Slides
This project focuses on the accelerated development of a high-spatial-resolution sequencing technology for the
co-mapping of transcriptomes and proteomes (hsrTP-seq) via deterministic barcoding in tissue, which will be
validated with paraformaldehyde(PFA)-fixed and formalin-fixed paraffin-embedded (FFPE) human tissue
specimens. This is a fundamentally new approach as compared to any existing spatial omics technologies. The
core idea is to molecularly barcode RNAs, proteins, or other biomolecular information in tissues using a novel
microfluidic in situ barcoding method. The tissue slide after barcoding remains morphologically intact but
consists of a mosaic of tissue pixels, each of which has a distinct DNA barcode. The size of the pixels is as
small as ~5-10μm, which is close to the size of individual cells. It is built upon the power of Illumina’s Next
Generation Sequencing (NGS) systems to achieve significantly higher sample high-throughput, lower cost, and
the elimination of laborious procedures for repeated single-molecule imaging as in seqFISH. It will demonstrate
high-spatial-resolution (~5-10μm pixel size), high-throughput (up to 100 tissue samples flow barcoded per day
per operator), and high-content (genome-wide mRNAs, proteins, and non-cellular environment). Using a panel
of DNA-tagged antibodies against extracellular matrix (ECM) proteins, this approach further allows for spatial
omics sequencing to include the mapping of non-cellular components, which are completely missing in scRNA-
seq or current spatial transcriptomics technologies. It is uniquely suited for mapping human collagenous
tissues including heart, aorta, skin, and kidney to improve our understanding of the role of ECM in normal
physiology, disease and aging. We will pursue the following specific aims. In the UG3 phase, we will develop a
set of new devices to significantly increase the tissue mapping area (4mmx4mm), develop a proteome-scale
(~500 proteins co-analyzed) and ECM-inclusive spatial sequencing, and develop a novel tissue optimization
protocol performed on the same tissue slide for hsrTP-seq, and generate a set of 3D spatial transcriptome-
proteome atlas data from human heart or aorta. In the UH3 phase, we will further develop a multi-pin injection
head to increase sample throughput (up to 100 samples per day) and the mapping area (1.2cmx1.2cm) for
further scale up and automation, develop a new in-tissue template switching method to retain intact tissue
section after hsrTP-seq for conducting other measurements on the same tissue slide and constructing 3D
tissue atlas, and finally develop an optimized PFA and FFPE tissue protocol to generate the 3D multi-omics
tissue atlas data (>20 tissue sections per sample) from the human heart, aorta, skin, and kidney.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.